Research
Environmentally friendly screen-printed electrodes for the selective detection of 4-bromo-2,5-dimethoxyphenethylamine (2C-B) in forensic analysis.
Analytical methods : advancing methods and applications – November 14, 2024
Summary
Repurposing discarded electronics for vital forensic work is now a reality. Researchers created an environmentally friendly sensor from recycled components to selectively detect the illicit drug 2C-B. This innovative device, requiring minimal sample, accurately identifies 2C-B in real-world samples. It offers a rapid, portable, and sensitive screening tool for forensic analysis, proving highly effective even amidst other substances.
Abstract
In response to the growing need for sustainable analytical methods, this study explores the repurposing of screen-printed electrodes (SPEs) that wo...
Knowledge, attitudes, and concerns about psilocybin and MDMA as novel therapies among U.S. healthcare professionals.
Scientific reports – November 14, 2024
Summary
Healthcare providers show strong support for psychedelic therapy, with psilocybin and MDMA gaining acceptance as promising treatments. In a survey of 879 medical professionals, most believed in these hallucinogens' therapeutic potential, particularly for depression and PTSD. While attitudes were positive, knowledge gaps exist about clinical applications and safety protocols.
Abstract
Psychedelic-assisted therapy (PAT) with substances like psilocybin and MDMA has shown promise for conditions including depression and post-traumati...
Effects of Different Anesthesia Applications on Mood, Depression, and Anxiety Levels in Burn Patients.
Journal of burn care & research : official publication of the American Burn Association – November 14, 2024
Summary
Ketamine-based sedation shows promising results in reducing depression and anxiety among patients with burns. A comprehensive analysis of 67 burn patients revealed that those receiving ketamine-based sedation experienced significant mood improvements and decreased anxiety levels after their procedures. While both traditional and ketamine-based methods proved effective, the ketamine group showed notably better results in managing depression symptoms. Remarkably, no participants displayed suicidal tendencies throughout the study period.
Abstract
Adequate and effective pain management and prevention of depression are essential in patients with burns. This study aims to explore the effects of...
About Distress in Chronic Pain Conditions: A Pre-Post Study on the Effectiveness of a Mindfulness-Based Intervention for Fibromyalgia and Low Back Pain Patients.
International journal of environmental research and public health – November 13, 2024
Summary
No Summary
Abstract
Chronic pain (CP) affects about 30% of the global population and poses significant challenges to individuals and healthcare systems worldwide. The ...
Multianalytical investigation reveals psychotropic substances in a ptolemaic Egyptian vase.
Scientific reports – November 13, 2024
Summary
No Summary
Abstract
This study presents a comprehensive multimodal analytical study of an Egyptian ritual Bes-vase, of the 2nd century BCE employing cutting-edge prote...
The Effect of Psilocybe cubensis on Spatial Memory and BDNF Expression in Male Rats Exposed to Chronic Unpredictable Mild Stress
Journal of Psychoactive Drugs – November 13, 2024
Summary
Psychedelics and Drug Studies reveal promising insights for chronic stress. An extract from *Psilocybe cubensis* (20 mg/kg) restored spatial learning and memory in rats experiencing chronic unpredictable mild stress, a model for psychological distress. This suggests a potential neurological and endocrinological pathway, as brain-derived neurotrophic factor (BDNF) levels, crucial for neuroscience, also increased. The timing of administration proved critical; a single dose 48 hours before training was most effective for memory, highlighting the complex neurotransmitter receptor influence on behavior. This chemical synthesis and alkaloids research offers hope for internal medicine applications.
Abstract
Psilocybin-containing mushrooms, commonly known as magic mushrooms, drastically affect mental processing, cognitive functioning, and the mood state...
Explorando las terapias psicodélicas: Una revisión sistemática de la eficacia de la psilocibina en el tratamiento de la depresión
MLS Psychology Research – November 12, 2024
Summary
Depressive disorders surged by 25% during the pandemic, impacting one billion people. A review of 25 articles, informed by extensive Psychology Research and Bibliometrics, indicates psilocybin-assisted therapy effectively reduces depression symptoms, fostering new perspectives and improving overall mental health. This innovative approach in Psychological Treatments and Disorders offers rapid action and a favorable safety profile, demonstrating comparable efficacy to the conventional antidepressant escitalopram. Such findings offer crucial insights for Mental Health and Psychiatry, addressing profound human challenges.
Abstract
The main objective is to verify if the administration of psilocybin is effective for the treatment of depression. In addition, the aim is to verify...
Crystal structure of an antibody specifically recognizing 3,4-methyl enedioxy methamphetamine through the epoxide moiety.
Biochemical and biophysical research communications – November 12, 2024
Summary
Scientists have achieved a breakthrough in developing antibodies that can distinguish MDMA (ecstasy) from similar drugs like METH. By analyzing the crystal structure of a specialized antibody, researchers revealed how it locks onto MDMA's unique epoxide moiety, creating a precise molecular fingerprint. This discovery enables more accurate drug testing and detection methods.
Abstract
3,4-methylenedioxymethamphetamine (MDMA) or publicly known as "ecstasy" is a drug abuse substance. Since antibodies that detect MDMA typically also...
Transformative Therapies for Depression: Postpartum Depression, Major Depressive Disorder, and Treatment-Resistant Depression
Annual Review of Medicine – November 11, 2024
Summary
Breakthroughs in medicine offer new hope for major depressive disorder, a condition with an enormous global economic burden. Brexanolone and zuranolone, the first FDA-approved drugs for postpartum depression, signify a critical advancement in maternal mental health. These transformative therapies provide rapid relief for a vulnerable population. Psilocybin also shows promise for treatment-resistant depression, signaling a significant stride in psychiatry and psychology. Such innovations aim to reshape treatment, impacting identity and memory through effective therapy.
Abstract
Depressive disorders present an enormous global public health burden. A notable treatment gap exists between the prevalence of depression and our a...
Ayahuasca rituals for the treatment of substance use disorders: Three narratives of former patients of a neo‐shamanic center from Uruguay
Anthropology of Consciousness – November 10, 2024
Summary
Ayahuasca, a psychedelic beverage from the Amazon, shows promise in treating substance use disorders (SUDs). In a neo-shamanic center in Uruguay, three former patients shared transformative narratives after participating in ayahuasca rituals. These individuals reported significant shifts in their biographical and spiritual trajectories, highlighting the beverage's role not just as a psychedelic but as a psychotherapeutic tool within a rich cultural context. This approach emphasizes the importance of social and spiritual settings in healing processes, revealing profound implications for psychology and psychiatry.
Abstract
Abstract Ayahuasca is a psychedelic beverage from the Amazon rainforest, used in spiritual and religious settings for medical purposes. Since the 1...
Esketamine-Induced Dissociation: A Case Report.
Journal of psychoactive drugs – November 10, 2024
Summary
A promising depression medication, esketamine, offers hope for those who don't respond to traditional treatments. While highly effective for treatment-resistant depression, this case highlights an important side effect: a patient experienced temporary but intense dissociation during therapy. Despite this adverse effect, she showed significant improvement in her depression symptoms, demonstrating esketamine's potential benefits when properly monitored.
Abstract
Esketamine, the isolated S-enantiomer of ketamine, has been a recent breakthrough as a non-monoaminergic treatment for treatment-resistant depressi...
Ketamine attenuates kidney damage and depression-like behaviors in mice with cisplatin-induced acute kidney injury.
Translational psychiatry – November 09, 2024
Summary
Ketamine, known primarily as an anesthetic, shows promise in treating both kidney damage and depression simultaneously. New research reveals that a single dose significantly reduced kidney injury and improved mood in mice with chemotherapy-related kidney damage. The treatment worked by activating specific brain pathways and altering blood chemicals, offering hope for patients dealing with both kidney problems and depression.
Abstract
Acute kidney injury (AKI) is a serious condition characterized by decreased urine output, often accompanied by psychiatric symptoms like depression...
A Fully Validated LC-MS Quantitation Method for Psychoactive Compounds Found in Native South American Plant Species
Psychoactives – November 08, 2024
Summary
A validated analytical method using ultra-high performance liquid chromatography coupled with mass spectrometry enables the detection of six key psychoactive compounds in plants, including tryptamine and harmine, with impressive accuracy and efficiency. The method achieved a limit of detection ranging from 0.06 to 0.11 ng/mL and extraction efficiency exceeding 98%. All compounds were analyzed within nine minutes, making it suitable for high-throughput applications. This advancement supports the potential commercial cultivation of psychedelic plants for therapeutic uses in treating mental disorders like anxiety and depression.
Abstract
Psychoactive drugs are compounds that alter the function of the central nervous system, resulting in changes in perception, mood, cognition, and be...
Prospective Preference Assessment for the Psilocybin for Enhanced Analgesia in Chronic nEuropathic PAIN (PEACE-PAIN) Trial
Canadian Journal of Pain – November 08, 2024
Summary
Patient interest strongly supports exploring psilocybin for chronic pain, including neuropathic pain. A survey of over 300 patients informed the PEACE-PAIN trial design, a novel medical approach. Psychology and drug studies guide its development. Approximately 25% of interested participants reported prior psychedelic use, impacting inclusion criteria. Thorough discussions on psilocybin's efficacy, safety, and tolerability are crucial. Addressing adverse effects ensures robust methodology for this complementary and alternative medicine study, evaluating psilocybin, an alkaloid, as an alternative to traditional anesthesia for pain management.
Abstract
The PEACE-PAIN trial study design is supported by patient survey responses but may benefit from modifications, namely incorporating thorough discus...
Development of the Japanese version of the Challenging Experience Questionnaire
Neuropsychopharmacology Reports – November 08, 2024
Summary
Understanding the full spectrum of human experiences with psychedelics is crucial for therapeutic use. To better assess challenging aspects, a team successfully developed a Japanese version of the Challenging Experience Questionnaire. They meticulously translated and back-translated the instrument, ensuring accuracy and cultural relevance. This positive development now enables Japanese speakers to evaluate difficult experiences during psychedelic-assisted therapy, a vital step for broader human research and clinical application.
Abstract
Abstract Introduction The therapeutic potential of psychedelics for various mental disorders has gained significant interest. Previous studies have...
Ethical Aspects of Psychedelic-Assisted Treatments: An Overview.
Current topics in behavioral neurosciences – November 08, 2024
Summary
No Summary
Abstract
In this chapter, we provide an overview of ethical aspects of psychedelic-assisted treatments in the areas of clinical ethics, research ethics, and...
Long-term effects of psilocybin on dynamic and effectivity connectivity of fronto-striatal-thalamic circuits
OpenAlex – November 07, 2024
Summary
Psilocybin, a psychedelic compound from chemical synthesis, profoundly reconfigures brain function. Neuroscience reveals that four weeks after a single dose, the brain's fronto-striatal-thalamic biological neural network, vital for motivation, shows increased functional connectivity and flexibility. Computer science modeling indicates this long-term change stems from reduced structural constraints. This re-organization, crucial for psychology, involves altered neurotransmitter receptor influence on behavior: reduced top-down control linked to 5-HT2A receptors and increased bottom-up flow via D2 receptors. These drug studies suggest a common mechanism for psilocybin's therapeutic potential.
Abstract
Abstract Psilocybin has been shown to induce fast and sustained improvements in mental well-being across various populations, yet its long-term mec...
Amid magic and menace: psychiatrists’ attitudes to psilocybin therapy
Irish Journal of Psychological Medicine – November 07, 2024
Summary
A significant 81.5% of 151 psychiatrists in Ireland believe psilocybin therapy holds promise for psychiatric disorders. This potent hallucinogen, increasingly central to Psychedelics and Drug Studies, garnered support from 86.8% who would refer patients if licensed. While 78.1% would consider this medicine for themselves, only 40.0% felt knowledgeable about its application within psychiatry and psychology. Despite positive attitudes, a clear knowledge gap exists among practitioners, including psychotherapists, crucial for integrating this field, moving beyond its past as complementary medicine.
Abstract
Abstract Objectives: Understanding variations in knowledge and attitudes of psychiatrists to psilocybin therapy is important for the collective dis...
Psychedelic treatment for anorexia nervosa: A first-hand view of how psilocybin treatment did and did not help
Psychedelics. – November 07, 2024
Summary
Psilocybin, a potent hallucinogen explored in psychedelics and drug studies, shows compelling promise for Anorexia nervosa, a severe psychiatric illness with high mortality. Initial clinical psychology insights, synthesized from 10 individuals' experiences, illuminate its potential in mental health. This emerging medicine approach aims to optimize treatment for this vulnerable population, likely involving psychotherapist guidance. Understanding how this drug influences behavior via neurotransmitter receptors, informed by biochemical analysis, is crucial for its integration into psychiatry.
Abstract
Anorexia nervosa (AN) is a psychiatric illness with high mortality rates and limited treatment outcomes. Psilocybin treatment (PT) has shown promis...
Correction: Azari et al. The Efficacy of Ketamine for Acute and Chronic Pain in Patients with Cancer: A Systematic Review of Randomized Controlled Trials. Healthcare 2024, 12, 1560.
Healthcare (Basel, Switzerland) – November 07, 2024
Summary
Ketamine, traditionally used as an anesthetic, shows promising results in managing cancer-related pain. This review analyzed multiple clinical trials and found that ketamine effectively reduced pain intensity in cancer patients, particularly when conventional painkillers weren't enough. Both short-term and long-term pain relief were observed, with minimal side effects.
Abstract
In the original publication [...].
S-ketamine alleviates depression-like behavior and hippocampal neuroplasticity in the offspring of mice that experience prenatal stress.
Scientific reports – November 06, 2024
Summary
Stress during pregnancy can significantly impact a child's mental health. New findings show that S-ketamine effectively treats depression in offspring exposed to prenatal stress by enhancing brain adaptability. The drug works by improving neuroplasticity in the hippocampus, a key brain region for emotional regulation, reversing stress-induced changes and boosting vital growth factors for healthy brain function.
Abstract
Prenatal stress exerts long-term impact on neurodevelopment in the offspring, with consequences such as increasing the offspring's risk of depressi...
Why N,N-dimethyltryptamine matters: unique features and therapeutic potential beyond classical psychedelics.
Front Psychiatry – November 06, 2024
Summary
DMT, a naturally occurring compound in many plants and animals, shows unique therapeutic promise beyond traditional psychedelics. Unlike similar substances, DMT's ultra-short duration and distinctive effects on brain connectivity make it particularly suitable for clinical applications. Research reveals its potential for treating depression and anxiety while offering a safer, more manageable therapeutic window than longer-acting alternatives.
Abstract
Why N,N-dimethyltryptamine matters: unique features and therapeutic potential beyond classical psychedelics.
Masking Influences: A Systematic Review of Placebo Control and Masking in Psychedelic Studies
Journal of Psychoactive Drugs – November 06, 2024
Summary
A critical review of nine **psychedelics and drug studies** reveals a significant challenge for **medicine**: nearly 78% had poor **masking** success. This means participants often knew if they received the active **chemical compounds**—like psilocybin or LSD, often from **chemical synthesis**, or natural **alkaloids**—or a **placebo**. This complicates attributing positive changes in **psychology** to the drug alone. For instance, 60-75% of **placebo** groups in **clinical psychology** still showed large effect sizes. **Psychotherapists** must consider these unmasking influences.
Abstract
Psychedelic-assisted therapy is becoming increasingly acknowledged as an effective therapeutic intervention for various psychiatric illnesses. Howe...
Global Trends in Psychedelic Microdosing: Demographics, Substance Testing Behavior, and Patterns of Use
Journal of Psychoactive Drugs – November 06, 2024
Summary
Exclusive psychedelic microdosers, a subset of 2488 individuals from a survey of 6193 consumers, exhibit distinct demographics and substance use patterns. They are older (46.4 vs. 42.0 years), predominantly female (68.4% vs. 44.7%), and report less non-psychedelic substance use (3.8 vs. 4.7 substances) compared to those also using macrodoses. Most microdose multiple times monthly, often with psilocybin (74.5%) or LSD (34.4%), primarily for wellbeing (73.0%), though 64.6% don't test their substances.
Abstract
Despite psychedelic microdosing being a growing practice, the research on the topic is still in its infancy. While several studies have described t...
Australian psychologists' attitudes towards psychedelic‐assisted therapy and training following a world‐first drug down‐scheduling
Drug and Alcohol Review – November 05, 2024
Summary
Australian psychologists largely embrace psychedelic-assisted therapy for mental health, viewing it as a promising psychological intervention. A nonprobability snowball sampling of 20 psychologists revealed most had positive attitudes towards these compounds, often products of chemical synthesis and alkaloids like psilocybin. However, limited knowledge and concerns about efficacy and adverse experiences were noted. This highlights the critical need for comprehensive medical education and training to ensure competence in this evolving area of clinical psychology and applied psychology, integrating diverse academic research themes from psychedelics and drug studies.
Abstract
Abstract Introduction This study explores the attitudes of psychologists towards psychedelics and psychedelic‐assisted therapy (PAT) following the ...
Exploring the substitution of cannabis for alcohol and other drugs among a large convenience sample of people who use cannabis.
Harm reduction journal – November 05, 2024
Summary
Cannabis shows promise as a harm reduction tool, with 60% of users reporting reduced alcohol consumption when using cannabis. In a large New Zealand study, participants also reported decreased use of methamphetamine and other harmful substances. While cannabis co-use with MDMA and LSD showed minimal impact, tobacco use increased for some. Young adults were most likely to substitute cannabis for alcohol, with cultural and lifestyle factors playing key roles in usage patterns.
Abstract
The substitution of cannabis for alcohol and other drugs has been conceptualised in a harm reduction framework as where cannabis is used to reduce ...
Enhanced visual contrast suppression during peak psilocybin effects: Psychophysical results from a pilot randomized controlled trial
Journal of Vision – November 05, 2024
Summary
Psilocybin profoundly alters visual perception, strengthening an effect called surround suppression where a high-contrast background reduces a central image's apparent contrast. A randomized controlled trial with 6 participants found a 25 mg psilocybin dose significantly increased this visual suppression compared to placebo. This finding, relevant to psychology and medicine, illuminates psilocybin's impact on sensory processing. The intensity of subjective psychedelic visuals correlated with this effect, offering insights for Psychedelics and Drug Studies into altered perception—relevant from audiology to paranormal experiences and beliefs—and informing complementary and alternative medicine.
Abstract
In visual perception, an effect known as surround suppression occurs wherein the apparent contrast of a center stimulus is reduced when it is prese...
Psilocybin Mushrooms and Public Health in Brazil: Insights from a Retrospective Analysis of Adverse Events and Their Implications for Regulatory Discussions
International journal of medicinal mushrooms – November 05, 2024
Summary
Psilocybin mushrooms present a remarkably low public health risk. Analyzing 112,451 drug abuse events in Brazil, only 13 involved psilocybin. While 6 of these (46.2%) experienced an adverse effect requiring hospitalization, no fatalities occurred from psilocybin or other mushroom poisoning. In stark contrast, 1.8% of all drug abuse events resulted in death, often linked to cocaine (33.3%). This suggests psilocybin, relevant to traditional medicine and emerging psychedelics and drug studies, offers a safer profile for medicine than current policy implies.
Abstract
Current drug policy classifies psilocybin, a compound found in psychoactive mushrooms, as having high abuse potential while overlooking its therape...
Proteomic analysis of psychedelic mushroom isolate and exploring potential antimicrobial peptides against bacteria.
Natural product research – November 05, 2024
Summary
Scientists discovered that magic mushrooms (Psilocybe cubensis) contain natural compounds that can fight harmful bacteria. Advanced protein analysis revealed several antimicrobial peptides that effectively combat S. aureus, a dangerous pathogen. These natural defenders could offer new ways to fight bacterial infections as traditional antibiotics lose effectiveness.
Abstract
Psychedelic mushrooms belonging to basidiomycota have gained prominence in research due to the range of hallucinogenic compounds. To combat the cha...
[Not Available].
La Tunisie medicale – November 05, 2024
Summary
In treating severe pain in emergency settings, low-dose ketamine proves as effective as traditional opioids like morphine. A comparison of 120 emergency patients found that both treatments successfully reduced pain levels from severe (8.7/10) to manageable levels within 10 minutes. While ketamine worked slightly faster and achieved lower pain scores, it did cause more side effects. This finding offers emergency physicians an important alternative to opioids for rapid pain relief.
Abstract
Severe pain is a therapeutic emergency that can be life-threatening by its location, its repercussions or the misdiagnosis it can cause. To investi...
The molecular structure, vibrational spectra, solvation effect, non-covalent interactions investigations of psilocin.
Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy – November 05, 2024
Summary
Scientists have decoded the molecular dance of psilocin, the active compound in psychedelic mushrooms, revealing how this therapeutic molecule behaves in different environments. Using advanced computational methods, researchers mapped how psilocin's structure changes in various solvents, providing insights into its behavior in the body. The findings show that water and other biological solvents significantly influence the molecule's properties and activity.
Abstract
Psilocin, or 4-HO-DMT (or 3-(2-dimethylaminoethyl)-1H-indol-4-ol), is a psychoactive alkaloid substance from the tryptamine family, isolated from P...
Therapeutic Potential of Psychedelic Compounds for Substance Use Disorders.
Pharmaceuticals (Basel, Switzerland) – November 05, 2024
Summary
Breakthrough treatments for addiction are emerging from an unexpected source: psychedelics. Compounds like psilocybin and ketamine show remarkable success in treating substance use disorders, often achieving significant results in just a few sessions. Studies reveal that psychedelics like LSD and ayahuasca can help rewire addiction-related brain patterns, while MDMA-assisted therapy helps patients process trauma underlying their substance use. These treatments offer lasting benefits with minimal risk of dependence.
Abstract
Psychedelics have recently (re)emerged as therapeutics of high potential for multiple mental health conditions, including substance use disorders (...
Preliminary safety and effectiveness of psilocybin-assisted therapy in adults with fibromyalgia: An open-label, pilot clinical trial
OpenAlex – November 04, 2024
Summary
A compelling new avenue for Fibromyalgia pain management emerges: five individuals undergoing Psilocybin-assisted therapy, guided by a psychotherapist, reported substantial improvements. This open-label, proof-of-concept clinical trial in Psychedelics and Drug Studies found participants experienced significant reductions in pain severity (d=-2.1) and sleep disturbance (d=-2.5) one month post-treatment. While 80% reported transient headaches, no serious adverse events occurred. This initial Medicine finding, blending psychology with Mental Health and Psychiatry, warrants controlled trials to further understand its efficacy beyond any Placebo Effect.
Abstract
Fibromyalgia (FM) is the prototypical nociplastic pain condition, characterized by widespread pain and issues with cognition, mood, and sleep. Curr...
Oxytocin and the Role of Fluid Restriction in MDMA-Induced Hyponatremia: A Secondary Analysis of 4 Randomized Clinical Trials.
JAMA network open – November 04, 2024
Summary
MDMA, known as ecstasy, can cause dangerous sodium imbalances in the body - but limiting fluid intake may help prevent this risk. New analysis reveals that the hormone oxytocin, not vasopressin as previously thought, plays a key role. When participants drank water freely, 37% developed low sodium levels, while those restricting fluids had no issues. This finding could make MDMA therapy safer.
Abstract
3,4-Methylenedioxymethamphetamine (MDMA, or ecstasy) is a recreational drug being investigated for the treatment of posttraumatic stress disorder. ...
Does the Perception of Risk Associated with Psychedelics Use Differ in Physicians According to Their Belief of Effectiveness?
Journal of psychoactive drugs – November 04, 2024
Summary
No Summary
Abstract
The aim of this study was to explore the perception of psychedelics within the medical population. Participants were asked by questionnaire about t...
Pyramidal cell types and 5-HT 2A receptors are essential for psilocybin’s lasting drug action
OpenAlex – November 03, 2024
Summary
Silencing specific brain cells can completely eliminate the therapeutic benefits of psilocybin. This hallucinogen, an alkaloid studied in psychedelics and drug studies, increases dendritic spine density in two pyramidal cell types. However, only subcortical-projecting (PT) neurons, when silenced, abolish the drug's action on stress-related behaviors. Psilocybin boosts synaptic activity and firing rates exclusively in PT neurons. This drug's action relies on the 5-HT2A receptor, a key neurotransmitter receptor influencing behavior. This neuroscience and pharmacology insight pinpoints PT cells and the 5-HT2A receptor as crucial for psilocybin's long-term effects.
Abstract
Abstract Psilocybin is a serotonergic psychedelic with therapeutic potential for treating mental illnesses 1–4 . At the cellular level, psychedelic...
Opioids Diminish the Placebo Antidepressant Response: A Post Hoc Analysis of a Randomized Controlled Ketamine Trial.
medRxiv : the preprint server for health sciences – November 02, 2024
Summary
Regular opioid use may block the power of placebo effects in treating depression, according to fascinating new findings. While non-opioid users showed significant improvement from placebo treatments, those taking opioids experienced less benefit. However, ketamine's antidepressant effects remained strong regardless of opioid use, suggesting it works through different pathways than traditional antidepressants and placebos.
Abstract
The endogenous opioid system is thought to play a role in the placebo antidepressant response. A recent trial comparing the rapid antidepressant ef...
Epistemic Risk Reduction in Psychedelic-Assisted Therapy.
Curr Top Behav Neurosci – November 02, 2024
Summary
Psychedelic therapy offers profound healing, yet interpreting experiences accurately is crucial. Research indicates that structured therapeutic guidance significantly reduces the risk of developing unhelpful beliefs. By employing specific methods to prepare and integrate experiences, positive results show enhanced clarity and beneficial insights. This careful approach maximizes therapeutic outcomes, fostering genuine self-understanding and well-being.
Abstract
Epistemic Risk Reduction in Psychedelic-Assisted Therapy.
Esketamine administered epidurally as an adjuvant to epidural ropivacaine for labour analgesia: a prospective, double-blind dose-response study.
BMJ open – November 02, 2024
Summary
Pain management during childbirth takes a leap forward with a breakthrough in obstetric anaesthesia. Adding esketamine to standard epidural medication reduces the amount of pain medication needed by up to 50%, while maintaining effective relief. This Chinese hospital study of 150 women found that combining these medications improved pain control during labor without affecting delivery outcomes. The optimal dose was identified, offering better pain management in obstetrics without significant side effects.
Abstract
To investigate the efficacy of esketamine as an adjuvant to epidural ropivacaine for labour analgesia by determining its effect on the median effec...
Retraction Note: MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials.
Psychopharmacology (Berl) – November 01, 2024
Summary
Remarkable findings from initial clinical trials suggested a novel approach for severe PTSD. Researchers explored how MDMA, when combined with specialized psychotherapy, could significantly reduce symptoms. A comprehensive analysis of six early-stage randomized controlled trials revealed positive results, demonstrating substantial improvement in participants' well-being. This innovative treatment strategy provided a strong rationale for advancing to larger-scale clinical trials as an effective PTSD treatment.
Abstract
Retraction Note: MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six p...
Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): commentary, Joks et al.
The British journal of psychiatry : the journal of mental science – November 01, 2024
Summary
Breakthrough findings show ketamine injections could offer new hope for people with severe depression who haven't responded to traditional treatments. Weekly subcutaneous doses significantly reduced depressive symptoms in patients with major depressive disorder, working faster than conventional medications. While esketamine nasal sprays are already approved, this injection method shows promise as an alternative delivery system.
Abstract
Regarding the article, 'Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KAD...
Protocol for Comparing Benzodiazepine-Ketamine and Benzodiazepine-Fentanyl Sedation in Phacoemulsification (BEKEF): A Double-Blind Crossover Non-Inferiority Clinical Trial Study.
Cureus – November 01, 2024
Summary
During cataract surgery, finding the right balance of sedation is crucial for patient comfort. Medical experts are evaluating whether ketamine could be a better partner to standard sedatives than fentanyl during phacoemulsification procedures. The study will track 48+ patients receiving both combinations across their two eyes, measuring sedation quality, surgical ease, and patient comfort. This research could revolutionize how doctors keep patients comfortable during these common but delicate procedures.
Abstract
Cataract surgery, particularly phacoemulsification, often requires sedation alongside topical anesthesia to manage patient anxiety and discomfort. ...
Recent Interventions for Acute Suicidality Delivered in the Emergency Department: A Scoping Review.
The western journal of emergency medicine – November 01, 2024
Summary
Emergency departments now have promising new tools to help suicidal patients. Ketamine and Crisis Response Planning (CRP) show particular potential for rapid intervention. Single-dose ketamine treatment and brief psychological interventions delivered in the ER helped reduce acute suicidal thoughts. While sample sizes were small, both approaches proved quick to implement and showed meaningful results in stabilizing patients during critical moments.
Abstract
Suicidality is a growing problem in the US, and the emergency department (ED) is often the front line for the management and effective treatment of...
Resting-State Electroencephalogram Complexity Is Associated With Oral Ketamine Treatment Response: A Bayesian Analysis of Lempel-Ziv Complexity and Multiscale Entropy.
Brain and behavior – November 01, 2024
Summary
Brain activity patterns may predict who will benefit from ketamine treatment for suicidal thoughts. Scientists found that patients who responded well to ketamine showed distinct electrical patterns in their brain's left frontal area during electroencephalogram recordings. Higher complexity in these brain signals before treatment was linked to better outcomes, suggesting doctors could potentially identify ideal candidates for ketamine therapy.
Abstract
Subanesthetic doses of ketamine are a promising novel treatment for suicidality; however, the evidence for predictive biomarkers is sparse. Recentl...
Effect of Esketamine Nasal Spray on Cognition in Patients With Treatment-Resistant Depression: Results From Four Phase 3 Studies.
The international journal of neuropsychopharmacology – November 01, 2024
Summary
Promising news for depression treatment: Nasal spray medication esketamine shows no negative impact on thinking and memory skills. In four major randomized controlled trials, patients with treatment-resistant depression who received esketamine maintained or slightly improved their cognitive performance. Using the Cogstate battery test, researchers tracked memory, attention, and processing speed, finding that patients' mental functions remained stable or enhanced during treatment.
Abstract
While esketamine is effective in treatment-resistant depression (TRD), detailed information about the effect of esketamine on cognition is relative...
Effects of Small-Dose Esketamine on Postoperative Analgaesia and Sleep Quality in Patients with Total Hip Replacement.
Journal of the College of Physicians and Surgeons--Pakistan : JCPSP – November 01, 2024
Summary
A promising alternative to traditional pain management after hip replacement has emerged: small doses of esketamine provide better pain relief with fewer complications than standard fentanyl treatment. Patients receiving esketamine needed pain medication later and required fewer doses overall. While sleep quality remained similar between treatments, esketamine patients avoided common issues like urinary retention that affected fentanyl users.
Abstract
To determine the effect of esketamine in patient-controlled analgaesia after hip replacement on postoperative pain and improve sleep quality in pat...
How Should We Expand Access to Psychedelics While Maintaining an Environment of Peace and Safety?
AMA journal of ethics – November 01, 2024
Summary
As psychedelic therapy gains mainstream acceptance, ketamine clinics offer valuable lessons for safely expanding access. Research shows that balancing medical oversight with personal autonomy is key - strict protocols protect vulnerable patients while avoiding over-medicalization. The solution involves clear guidelines distinguishing between clinical treatment and wellness applications, with appropriate safeguards for each path.
Abstract
Psychedelics have long been used by individuals seeking peace and a sense of wellness. This article examines widespread adoption of ketamine as a p...
FDA Denies Approval of MDMA-Assisted Therapy for PTSD.
The American journal of nursing – November 01, 2024
Summary
Despite promising Phase 3 trials, regulators declined to approve MDMA-assisted psychotherapy for PTSD treatment, citing safety concerns and methodological issues in clinical studies. The decision impacts thousands of veterans and trauma survivors who showed significant symptom improvement in controlled therapeutic settings. Officials requested additional safety data and stricter protocols before reconsideration.
Abstract
The agency cited potential dangers and flaws in research methodology.
Morphological correlates of anxiety-related experiences during a ketamine infusion.
The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry – November 01, 2024
Summary
Brain size matters when it comes to ketamine experiences. New findings reveal that people with smaller hippocampus regions tend to experience more anxiety during ketamine treatment. By examining brain morphology through advanced imaging, researchers found that the size of specific brain areas, particularly the hippocampus and amygdala, can predict how individuals might react to ketamine therapy. This insight could help doctors better prepare patients for treatment.
Abstract
Ketamine exerts rapid antidepressant effects by enhancing neuroplasticity, particularly in the amygdala and hippocampus-regions involved in fear pr...
Effective action of silymarin against ketamine-induced schizophrenia in male mice: Insight into the biochemical and molecular mechanisms of action.
Journal of psychiatric research – November 01, 2024
Summary
A natural compound found in milk thistle shows promise in treating psychosis and schizophrenia-like symptoms. The plant-based antipsychotic, silymarin, effectively prevented and reversed behavioral changes in mice by reducing neuroinflammation and restoring brain chemistry balance. Unlike traditional medications, it improved both positive and negative symptoms without serious side effects, marking a potential breakthrough in neuropharmacology.
Abstract
Neurochemical dysregulations resulting from N-methyl-D-aspartate hypofunction (NMDA), are exacerbated by neuroimmune and oxidative stress and are k...
KETAMINE: Neural- and network-level changes.
Neuroscience – November 01, 2024
Summary
Ketamine's remarkable ability to reshape brain connectivity offers new hope for treating mental health conditions. This groundbreaking research reveals how ketamine enhances neuroplasticity by promoting hyperconnectivity between brain regions and fine-tuning neural responses. The drug increases neural synchrony across brain networks while reducing firing variability, creating more robust connections between neurons. These changes in brain circuitry help explain ketamine's powerful therapeutic effects and its potential to rapidly improve mood disorders.
Abstract
Ketamine is a widely used clinical drug that has several functional and clinical applications, including its use as an anaesthetic, analgesic, anti...
Novel harm reduction measures at music festivals in Australia: Pilot implementation of the Emerging Drugs Network of Australia-Victoria toxicosurveillance methodology.
Drug and alcohol review – November 01, 2024
Summary
At Australian music festivals, 75% of critically ill patients tested positive for unexpected substances, revealing the hidden risks of illicit drugs. New public health monitoring systems track drug-related emergencies at festivals, analyzing blood samples for over 700 substances. The program identified dangerous new psychoactive substances (NPS) and helped medical teams provide better care, ultimately making festivals safer through enhanced toxicosurveillance.
Abstract
Harm reduction strategies at music festivals seek to create a safer environment for patrons. The Emerging Drugs Network of Australia-Victoria (EDNA...
Glutamatergic Modulators for Major Depression from Theory to Clinical Use.
CNS drugs – November 01, 2024
Summary
Breakthrough brain chemistry findings have led to faster-acting depression treatments. While traditional antidepressants take weeks to work, new medications targeting glutamate - a key brain chemical - can provide relief within days. Two FDA-approved treatments now harness this mechanism: a nasal spray for treatment-resistant depression and a novel oral medication. These options offer hope for patients who don't respond to conventional therapies.
Abstract
Major depressive disorder (MDD) is a chronic, burdensome, highly prevalent disease that is characterized by depressed mood and anhedonia. MDD is es...
Rethinking the role of TRKB in the action of antidepressants and psychedelics.
Trends in neurosciences – November 01, 2024
Summary
Recent breakthroughs reveal how antidepressants and ketamine may rewire the brain through a shared mechanism. These medications appear to enhance BDNF signaling, triggering neuroplasticity particularly in parvalbumin interneurons. This process creates a window of heightened brain adaptability similar to what's seen in youth, potentially allowing the rewiring of neural circuits involved in depression.
Abstract
Antidepressant drugs promote neuronal plasticity, and activation of brain-derived neurotrophic factor (BDNF) signaling through its receptor neurona...
How Psychedelics Modulate Multiple Memory Mechanisms in Posttraumatic Stress Disorder.
Drugs – November 01, 2024
Summary
No Summary
Abstract
Posttraumatic stress disorder (PTSD) is a psychiatric disorder with defining abnormalities in memory, and psychedelics may be promising candidates ...
Classical psychedelics' action on brain monoaminergic systems.
The international journal of biochemistry & cell biology – November 01, 2024
Summary
No Summary
Abstract
The study of the mechanism of action of classical psychedelics has gained significant interest due to their clinical potential in the treatment of ...
The role of NMDA-receptor type glutamatergic antagonists dextromethorphan or ketamine in the treatment of nonketotic hyperglycinemia: A critical reassessment.
Molecular genetics and metabolism – November 01, 2024
Summary
A surprising shift in understanding Nonketotic hyperglycinemia's pathophysiology is emerging. While excess glycine was once thought to overactivate brain receptors, leading to trials with Dextromethorphan or Ketamine, new insights reveal a crucial activator is actually *decreased*. This challenges the initial hypothesis, as clinical evidence hasn't shown these drugs provide added benefit. A critical reevaluation of Dextromethorphan and Ketamine's systematic use is vital for optimal patient care.
Abstract
The recognition of glycine as an endogenous ligand at the allosteric activation site of the NMDA-type glutamatergic receptor led to the assumption ...
Effect of meditation or escitalopram on work performance in patients with anxiety disorders.
Journal of affective disorders – November 01, 2024
Summary
No Summary
Abstract
This study aimed to 1) examine how psychopharmacotherapy and mindfulness-based stress reduction (MBSR) influence absenteeism and job performance am...
Phytochemical screening, phenolic and flavonoid contents, psilocybin, antioxidant, and acetylcholinesterase inhibition activities of the aqueous extract from the fungi Cyathus striatus, Laternea dringii, and Marasmius haematocephalus
Brazilian Journal of Science – November 01, 2024
Summary
Certain mushrooms exhibit remarkable potential for neuroprotection. Extracts from *Marasmius haematocephalus* showed strong acetylcholinesterase inhibition at 77.14%, with *Laternea dringii* at 68.53%, suggesting applications for Neurodegenerative Diseases. These fungi, significant in Fungal Biology and Applications, contain diverse phytochemicals, including flavonoids (up to 56.06 mg QE g TFC-1). Their natural chemistry offers antioxidant benefits. While chemical synthesis and alkaloids are explored, the investigation also considered psilocybin, aligning with traditional medicine's interest in fungal compounds.
Abstract
Various families of mushrooms contain important phytochemicals with significant potential. This study aimed to investigate the phytochemical prospe...
Preliminary Evidence of Sleep Improvements Following Psilocybin Administration, and their Involvement in Antidepressant Therapeutic Action
Current Psychiatry Reports – November 01, 2024
Summary
Severe insomnia and sleep disturbances can hinder psilocybin's antidepressant effects in treating major depressive disorder. While clinical trials demonstrate large improvements in depressive symptoms, psilocybin's direct impact on sleep quality has been less explored in psychology and psychiatry. Preliminary clinical psychology data suggests both depression and sleep issues decrease after psilocybin use, though sleep improvements are smaller. This highlights a critical intersection for mental health research topics and medicine. Addressing sleep, perhaps related to tryptophan pathways, could optimize psychedelic-assisted therapy, leading to more effective strategies in drug studies and clinical trials for depression.
Abstract
Abstract Purpose of the study Psilocybin is a rapidly-emerging treatment for depression, yet its impact on sleep is not well understood. We sought ...